Linda Zuckerman, PhD, brings over 20 years of biologics drug development experience to Just – Evotec Biologics including executive-level accountability for preclinical, clinical, and regulatory functions as well as business development and portfolio management activities. Prior to joining Just, Linda served as CEO of two small start-ups and was the President of ProFibrix, Inc., overseeing US-based biologics drug development activities as well as its operations.
Linda has also worked at Genentech and ZymoGenetics/BMS overseeing biologics development activities and contributed significantly to the approvals and commercialization of Raplixa (US & EU), Recothrom, and Raptiva and the filing many INDs in the areas of autoimmunity, hemostasis, and oncology. Linda received her PhD in immunology from the University of Chicago and has expertise in the regulatory aspects of the immunogenicity of biotherapeutics.